{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:40:09Z","timestamp":1748972409080,"version":"3.41.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir\/ritonavir\u2013ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily. However, this dosing may not be applicable to all patients depending on their clinical condition. This study focuses on the pharmacokinetic dynamics of PrOD with CsA in Asian organ transplant recipients with severe liver fibrosis or cirrhosis who undergo concurrent treatment with PrOD treatment and CsA. The efficacy and safety of PrOD treatment was also evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data from 7 patients obtained between January 2017 and September 2017 were retrospectively analyzed. Determinations of the blood concentrations of CsA were made, whether used as a single treatment or in combination therapy with PrOD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The combination regimen compared with CsA administered alone resulted in a 4.53-fold and 5.52-fold increase in the area under the concentration\u2013time curve from time 0\u201312 hours (AUC<jats:sub>0\u201312 h<\/jats:sub>) of CsA on days 1 and 15, respectively. In addition, the maximal concentration, time to maximum concentration, and terminal phase elimination half-life (t<jats:sub>1\/2<\/jats:sub>) of CsA were increased during the combined treatment of PrOD and CsA. The authors proposed reducing the CsA dosage during PrOD treatment to one-seventh of that of the pre-PrOD treatment of the total daily dose to maintain target CsA levels. All patients achieved sustained virologic responses at week 12. There were no episodes of serious adverse events or graft rejections observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000967","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T15:00:41Z","timestamp":1643554841000},"page":"377-383","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Drug\u2013Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir\/Ritonavir\u2013Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis"],"prefix":"10.1097","volume":"44","author":[{"given":"Ying-Yu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Hung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Chuan","family":"Loong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9795-1747","authenticated-orcid":false,"given":"Yuh-Lih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","first-page":"161","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"Singal","year":"2013","journal-title":"Transplantation."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/sdi.12757","article-title":"The epidemiology of HCV infection in patients with advanced CKD\/ESRD: a global perspective","volume":"32","author":"Fabrizi","year":"2019","journal-title":"Semin Dial."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1034\/j.1399-0012.2002.1o034.x","article-title":"Strey C and Grotz WH Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation","volume":"16","author":"Breitenfeldt","year":"2002","journal-title":"Clin Transpl."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/TP.0000000000001953","article-title":"Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the United States","volume":"102","author":"Heo","year":"2018","journal-title":"Transplantation."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.tp.0000259725.96694.0a","article-title":"Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival","volume":"83","author":"Maluf","year":"2007","journal-title":"Transplantation."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00007890-199510000-00007","article-title":"The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation","volume":"60","author":"Periera","year":"1995","journal-title":"Transplantation."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/HMER.S11916","article-title":"A meta-analysis that compares the use of either peginterferon-alpha2a or peginterferon-alpha2b plus ribavirin for HCV infection","volume":"2","author":"Xiao","year":"2010","journal-title":"Hepat Med."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"Electronic address EEE EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am J Transpl."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FTD.0000000000000315","article-title":"Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection","volume":"38","author":"Badri","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"e13510","DOI":"10.1111\/ctr.13510","article-title":"Interactions between anti-infective agents and immunosuppressants-guidelines from the American society of transplantation infectious diseases community of Practice","volume":"33","author":"Sparkes","year":"2019","journal-title":"Clin Transpl."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13318-018-0492-8","article-title":"Pharmacokinetics of ombitasvir, paritaprevir, ritonavir, and dasabuvir in healthy Chinese subjects and HCV GT1b-infected Chinese, south Korean and Taiwanese patients","volume":"44","author":"Zha","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0091270002239704","article-title":"Pharmacokinetics of cyclosporine pre- and post-liver transplantation","volume":"43","author":"Hebert","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"R21-20250603","first-page":"471","article-title":"Bridson JM and Halawa A calcineurin inhibitor-sparing strategies in renal transplantation: where are we? A comprehensive review of the current evidence","volume":"14","author":"Camilleri","year":"2016","journal-title":"Exp Clin Transpl."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group","volume":"20","year":"1994","journal-title":"Hepatology."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.transproceed.2018.01.006","article-title":"Ombitasvir-paritaprevir-ritonavir therapy in a kidney transplant recipient with chronic hepatitis C virus genotype 1 infection: a case report on the importance of considering drug-drug interactions and monitoring cyclosporine levels","volume":"50","author":"Takeuchi","year":"2018","journal-title":"Transpl Proc."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12328-018-0884-y","article-title":"Three renal failure cases successfully treated with ombitasvir\/paritaprevir\/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation","volume":"12","author":"Orita","year":"2019","journal-title":"Clin J Gastroenterol."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"695","DOI":"10.5152\/tjg.2019.18833","article-title":"Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection","volume":"30","author":"Danis","year":"2019","journal-title":"Turk J Gastroenterol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gene.2018.04.043","article-title":"Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: a meta-analysis","volume":"664","author":"Wang","year":"2018","journal-title":"Gene."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clpt.2004.08.022","article-title":"Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes","volume":"76","author":"Hesselink","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bcpt.12371","article-title":"The effect of ABCB1 C3435T polymorphism on cyclosporine dose requirements in kidney transplant recipients: a meta-analysis","volume":"117","author":"Lee","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1440-1681.2006.04492.x","article-title":"Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation","volume":"33","author":"Hu","year":"2006","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00007890-198604000-00009","article-title":"Lorber MI and Van Buren CT Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay","volume":"41","author":"Kahan","year":"1986","journal-title":"Transplantation."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:15:08Z","timestamp":1748970908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000967","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-07-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}